Relacs Health

12/23/2025

Andy Berkowski, MD of Relacs Health reviews the major stories from 2025 for the management of restless legs syndrome (RLS), and previews changes to the field for 2026.

2025 was a landmark year for the treatment of restless legs syndrome (RLS). of ReLACS Health reviews the top 5 stories from 2025 heading int...

11/04/2025

A little easier to wake up this morning than in March for Daylight Saving Time? Andy Berkowski, MD of ReLACS Health explains why.

of ReLACS Health describes why turning the clock back in the fall is easier than springing forward. Though sleep expert consensus is in favo...

11/02/2025

This is a well-written AARP article summarizing RLS and highlighting the important updated treatment approach laid out by the American Academy of Sleep Medicine.

​If you have an uncontrollable urge to move your legs at night, you might have RLS. Learn how it develops, who’s at risk and how to ease your symptoms​

11/01/2025

Answer to some of the differences between buprenorphine and tramadol, which are unique opioids in the treatment of RLS.

10/11/2025

This is a well-written personal account of a therapist's experience with her own battle with restless legs syndrome (RLS). (requires Medium account to access)

PART ONE: AN INCURABLE DISEASE

09/19/2025

This year's RLS Foundation Virtual Summit is tomorrow, Saturday 19 at 11 am EDT. Register today! Andy Berkowski, MD of Relacs Health joins other national experts in presenting including a live Q & A to conclude the summit.

Register for our 2025 Virtual Summit! This all-day event explores the latest in technology, treatments, and approaches to managing RLS. Our featured presenters are leading RLS and sleep physicians, researchers and professionals. Attendees can submit questions during each session, to be asked and ans...

09/08/2025

Good news for those suffering with restless legs syndrome (RLS), Noctrix Health, the maker of the Nidra peroneal nerve stimulator device, is ramping up its availability in the US and hopefully internationally. The Nidra is the only device recommended in the 2025 American Academy of Sleep Medicine Clinical Practice Guidelines for the treatment of RLS. Due to dopamine agonist therapy, the previous mainstay of treatment, making RLS significantly worse with long-term use, those with RLS are in desperate need of alternative treatments, particularly non-medication ones like the Nidra.

ACCESS Newswire is the leading global press release distribution service. Tell your story and reach millions of journalists. Contact us today to get started.

09/06/2025

For those not yet signed up for the Restless Legs Syndrome Foundation 2025 Virtual Summit on Sep. 20, the early bird deadline has been extended to Saturday, September 13. Andy Berkowski, MD of Relacs Health will be presenting on navigating the health care system with RLS as well as participating in a live Q & A.

Register for our 2025 Virtual Summit! This all-day event explores the latest in technology, treatments, and approaches to managing RLS. Our featured presenters are leading RLS and sleep physicians, researchers and professionals. Attendees can submit questions during each session, to be asked and ans...

08/30/2025

Finding the new restless legs syndrome (RLS) guidelines by the American Academy of Sleep Medicine a little too technical? Andy Berkowski, MD of Relacs Health has co-authored a plain language summary of the AASM Guidelines, written for non-medical people, just out this week.

Published in Expert Review of Neurotherapeutics (Ahead of Print, 2025)

08/03/2025

Join us for the RLS Foundation's 2025 Virtual Summit. Once again, Andy Berkowski, MD of Relacs Health will be presenting with this year's webinar "Modern Paths: Navigating Healthcare Options for RLS" as well as taking your questions at the end as part of the webinar's Q & A expert panel. Register soon for early bird pricing.

Register for our 2025 Virtual Summit! This all-day event explores the latest in technology, treatments, and approaches to managing RLS. Our featured presenters are leading RLS and sleep physicians, researchers and professionals. Attendees can submit questions during each session, to be asked and ans...

07/29/2025

Most know that dopamine agonists are recommended AGAINST in the treatment of restless legs syndrome (RLS) due to augmentation, an insidious worsening of the condition over time. However, impulse control disorders are an equally devastating effect of the drug class. Noel Titheradge in his second investigative piece on these drugs for the BBC details the disturbing sexual impulse problems that are common but often fly under doctors' radars.

The prescribed medication, taken for movement disorders, can have extreme side effects.

06/24/2025

On the heels of the national SLEEP 2025 Conference, Andy Berkowski, MD of Relacs Health writes about the explosion of interest in RLS this year as well as the need to get the message out to primary care clinicians who are likely to be the first to start off RLS patients on the wrong leg (or foot).

The SLEEP 2025 conference represented a funeral for the dopaminergic drug class for treating restless legs syndrome (RLS). How long will it take to...